Ascendis Pharma A/S (ASND)
252.99
+1.04
(+0.41%)
USD |
NASDAQ |
Aug 25, 16:00
253.31
+0.32
(+0.13%)
After-Hours: 06:23
Ascendis Pharma Net Income (Quarterly) : 240.65M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 240.65M |
| March 31, 2026 | 736.28M |
| December 31, 2025 | -39.06M |
| September 30, 2025 | -71.27M |
| June 30, 2025 | -44.04M |
| March 31, 2025 | -99.59M |
| December 31, 2024 | -41.03M |
| September 30, 2024 | -108.97M |
| June 30, 2024 | -117.75M |
| March 31, 2024 | -142.22M |
| December 31, 2023 | -93.43M |
| September 30, 2023 | -176.47M |
| June 30, 2023 | -132.16M |
| March 31, 2023 | -119.00M |
| December 31, 2022 | -211.58M |
| September 30, 2022 | -170.09M |
| June 30, 2022 | -86.54M |
| March 31, 2022 | -140.79M |
| December 31, 2021 | -121.23M |
| September 30, 2021 | -94.71M |
| June 30, 2021 | -162.00M |
| March 31, 2021 | -75.63M |
| December 31, 2020 | -165.67M |
| September 30, 2020 | -142.29M |
| June 30, 2020 | -104.55M |
| Date | Value |
|---|---|
| March 31, 2020 | -69.75M |
| December 31, 2019 | -88.97M |
| September 30, 2019 | -27.92M |
| June 30, 2019 | -66.19M |
| March 31, 2019 | -60.90M |
| December 31, 2018 | -36.49M |
| September 30, 2018 | -39.51M |
| June 30, 2018 | -27.12M |
| March 31, 2018 | -50.85M |
| December 31, 2017 | -40.24M |
| September 30, 2017 | -39.80M |
| June 30, 2017 | -33.82M |
| March 31, 2017 | -26.79M |
| December 31, 2016 | -17.73M |
| September 30, 2016 | -20.37M |
| June 30, 2016 | -15.00M |
| March 31, 2016 | -22.62M |
| December 31, 2015 | -13.13M |
| September 30, 2015 | -8.125M |
| June 30, 2015 | -16.64M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | -6.293M |
| September 30, 2014 | -2.623M |
| June 30, 2014 | -2.932M |
| March 31, 2014 | -0.6878M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Evaxion AS | -3.724M |
| Genmab A/S | 302.57M |
| Zealand Pharma A/S | 609.41M |
| Cellectis SA | -21.79M |
| BioMarin Pharmaceutical, Inc. | 44.76M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 394.49M |
| Total Expenses (Quarterly) | 153.84M |
| EPS Diluted (Quarterly) | 3.522 |
| Enterprise Value | 16.20B |
| Gross Profit Margin (Quarterly) | 90.64% |
| Profit Margin (Quarterly) | 61.00% |
| Earnings Yield | 5.19% |
| Operating Earnings Yield | 0.78% |
| Normalized Earnings Yield | 5.188 |